AbbVie reports 99% cure rate for pan-genotypic Hep C therapy

21st April 2017 Uncategorised 0

AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.

More: AbbVie reports 99% cure rate for pan-genotypic Hep C therapy
Source: News